According to a report, Houston lost over 3,000 innovation jobs between 2005 and 2017. Joe Daniel Price/Getty Images

You've heard of brain drain, the phenomenon of well-educated, highly skilled workers fleeing a geographic area for better opportunities elsewhere. It appears Houston is grappling with a different workforce affliction: innovation drain.

Houston is among several major business hubs in the U.S. — including Dallas-Fort Worth, Los Angeles, Philadelphia, and Washington, D.C. — where tech-dependent "innovation" jobs evaporated from 2005 to 2017, according to report released December 9 by the Brookings Institution think tank and the Information Technology & Innovation Foundation. At those cities' expense, innovation jobs have clustered in Boston, San Francisco, San Jose, Seattle, and San Diego. Those five metro areas accounted for more than 90 percent of job growth in the innovation sector from 2005 to 2017, researchers found.

Today, one-third of innovation jobs in the U.S. are located in just 16 counties, and more than half are concentrated in 41 counties, according to the report.

The report shows the Houston metro area lost 3,281 tech-oriented innovation jobs during that period. Dallas-Fort Worth lost even more (8,969), while the Austin metro area gained 1,200 and the San Antonio metro area picked up 1,472.

Houston's loss represents a slippage of 0.2 percent in the region's share of innovation jobs in the U.S., the report notes. On a percentage basis, DFW sustained an even greater loss (0.5 percent), while Austin's share declined 0.1 percent and San Antonio's didn't budge.

On the positive side, Houston ranked 14th for its sheer number of innovation jobs, with Dallas-Fort Worth at No. 7 and Austin at No. 16. They were among 20 "superstar" metro areas singled out in the report.

In the report, researchers classify innovation jobs as those in 13 R&D-heavy sectors, including aerospace, computer manufacturing, chemical production, and telecom. While the 13 innovation segments account for only 3 percent of U.S. jobs, they represent 6 percent of the country's economic output (GDP), one-fourth of exports, and two-thirds of corporate R&D expenditures, the report says.

Responding to the Brookings analysis, Susan Davenport, senior vice president of economic development at the Greater Houston Partnership, notes the Houston area employs about 150,000 tech workers, many of whom are employed outside the 13 innovation industries mentioned in the report. In fact, she adds, Houston boasts the highest share of tech workers at non-tech companies among the country's 20 largest metro areas.

"That said, we recognize the need to build Houston's digital tech presence, an area where we have traditionally lagged," Davenport tells InnovationMap.

Houston is making headway on that front, though. Davenport cites the expansion of Microsoft Corp.'s local operations, the recent opening of Bill.com's Houston office, and the rise of three Houston entrepreneurship initiatives — The Ion, TMC3, and The Cannon — as examples of this progress.

"Houston continues to gain recognition as a leading tech city," Davenport says. "The region cleared $500 million in venture capital funding this year, a new high for Houston, and tech-related employment continues to grow within the energy industry. We continue working with our partners to grow Houston's innovation ecosystem and are excited for the great momentum in this area."

Investor and entrepreneur Harvin Moore, president of Houston Exponential, a nonprofit that promotes startups and innovation, acknowledges the region's historical lack of focus on the innovation economy contributed to Amazon bypassing Houston as a finalist in 2018 for the e-commerce giant's second headquarters. Despite that harsh reality, Moore says the Brookings report fails to take into account innovation jobs embedded in sectors like Houston's massive energy industry.

"That data issue will always penalize a city with a large energy sector until it is corrected," Moore says. "And as we know, the energy sector is starting to innovate rapidly, as it must. And that innovation draws more employees to those companies and to Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.